Glucosio Con Sodio Cloruro Fresenius Kabi Italia

Glucosio Con Sodio Cloruro Fresenius Kabi Italia is an intravenous solution that combines sodium chloride and glucose monohydrate in a sterile solution for injection. The product is supplied without a specified concentration, conforming to EU pharmaceutical standards. It is classified as an IV electrolyte and carbohydrate solution and is available by prescription only. The formulation is intended for infusion into the bloodstream under medical supervision.

Glucosio Con Sodio Cloruro Fresenius Kabi Italia is indicated for several therapeutic situations that require isotonic fluid and carbohydrate support.

- Replacement of extracellular fluid losses in dehydration or hemorrhage. - Maintenance of hydration and electrolyte balance after surgery. - Support of plasma osmolarity in critically ill patients. - Provision of glucose for patients at risk of hypoglycemia. - Adjunct therapy during parenteral nutrition when additional electrolytes are needed. - Facilitation of drug dilution for intravenous administration when compatible.

The safety profile of Glucosio Con Sodio Cloruro Fresenius Kabi Italia reflects the expected effects of isotonic saline and glucose solutions administered intravenously.

Common: - Mild irritation at the infusion site. - Transient increase in blood glucose levels. - Slight electrolyte shifts causing temporary nausea. - Headache. - Dizziness.

Serious: - Hypernatremia or severe electrolyte imbalance. - Hyperglycemia leading to osmotic diuresis. - Fluid overload with pulmonary edema. - Anaphylactic reaction to excipients. - Severe metabolic acidosis in susceptible patients.

When prescribing Glucosio Con Sodio Cloruro Fresenius Kabi Italia, clinicians should consider patient-specific factors and monitor relevant parameters.

- Assess baseline serum electrolytes and glucose before infusion. - Adjust infusion rate in patients with renal or cardiac impairment. - Avoid rapid administration in neonates and infants. - Monitor for signs of fluid overload during prolonged therapy. - Use aseptic technique to prevent catheter‑related infections. - Re‑evaluate electrolyte status regularly during treatment.

Glucosio Con Sodio Cloruro Fresenius Kabi Italia may interact with other intravenous or oral agents that affect fluid, electrolyte, or glucose balance.

Avoid: - Concurrent high‑dose potassium chloride solutions without monitoring. - Co‑administration with hypertonic glucose preparations.

Use with caution: - Diabetic medications (insulin, oral hypoglycemics) – monitor blood glucose. - Loop diuretics – risk of electrolyte depletion. - ACE inhibitors or ARBs – potential for altered renal handling of sodium. - Blood products – ensure compatible infusion rates. - Corticosteroids – may exacerbate hyperglycemia.